/

AKBA

Akebia Therapeutics, Inc.Closed

0.7700−0.02 −2.56%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.7740 +0.52%

Open

0.8000

Prev close

0.7902

Day range

0.76550.8049

52-week range

0.76553.20

Volume

6.50M1.03×

Mkt cap

213.37M

P/E ttm

—

Fwd P/E

-2.14

EPS ttm

-0.1200

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−75.94%

Price Chart

Yahoo Finance · delayed

AKBAOct 13, 2026O 0.8000H 0.8050L 0.7660C 0.7700−0.0200 (−2.53%)Vol 6.50M

SMA 500.9210
SMA 2001.2025

1Y change −72.00% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AKBA Akebia Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −12.40%
1 month: −19.12%
3 months: −45.00%
6 months: −50.64%
Year to date: −52.17%
1 year: −72.30%

Valuation & ownership

Market cap: 213.37M
Enterprise value: 257.01M
P/E (ttm): —
Forward P/E: -2.14
PEG ratio: —
Price / book: 8.37
Price / sales (ttm): 0.97
EV / EBITDA: -59.83
EPS (ttm): -0.1200
EPS (forward): -0.3600
Beta (5y monthly): 0.18
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 277.11M
Float: 272.25M
Short % of float: 8.23%
Short ratio (days): 3.07
Held by insiders: 1.98%
Held by institutions: 40.78%
Avg volume (3m): 6.29M
50-day average: 0.9318
200-day average: 1.21
52-week change: −72.30%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 32.6
vs 50-day SMA: −16.40%
vs 200-day SMA: −35.97%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.37%
Realised vol (20d, ann.): 51.8%
From 52-week high: −75.94%
From 52-week low: +0.52%

ANR

Analyst Consensus

6 analysts

Consensus

—

Mean target

3.92

+408.66% implied

Low 1.00Median 4.00High 6.00

Recommendation trend

Now5 / 1 / 0
1m ago4 / 1 / 0

DES

About Akebia Therapeutics, Inc.

Yahoo Finance profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 194
Headquarters: Waltham, MA, United States
Website: akebia.com
Officers: Mr. John P. Butler MBA CEO, President & Director

SEAS

Seasonality · AKBA

2014–2026 · monthly returns

Strongest month Nov +13.01%Weakest month Oct −11.75%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-12.4	-7.1	6.1	-0.7	-26.1	11.8	15.8	-30.4	0.1	-16.3			−52.2%
2025	17.9	-17.4	3.8	25.5	25.7	20.1	1.2	-14.8	-13.1	-19.0	-28.5	1.9	−15.3%
2024	35.5	-6.0	15.8	-31.1	-11.1	-8.9	35.3	12.3	-14.8	25.8	24.1	-7.8	+53.2%
2023	9.2	33.8	-33.6	62.3	14.4	-12.0	82.5	-16.8	-18.0	-22.8	20.5	17.0	+114.9%
2022	-11.9	8.5	-66.8	-42.2	-10.8	-4.6	10.8	-6.9	-13.2	-19.3	6.3	112.9	−74.5%
2021	15.7	6.8	-2.2	-5.8	10.0	8.0	-34.8	19.0	-2.0	-0.3	-5.6	-16.6	−19.3%
2020	14.2	22.9	-14.5	6.9	43.7	16.7	-17.7	-6.8	-75.9	-11.6	49.1	-15.4	−55.7%
2019	-0.4	32.1	12.5	-26.3	-26.3	8.8	-13.4	-1.4	-5.1	-4.8	68.6	0.5	+14.3%
2018	-0.6	-3.2	-33.4	-3.4	6.6	1.6	3.2	-20.3	7.6	-15.2	7.9	-31.6	−62.8%
2017	-3.7	-0.1	-8.2	43.3	1.7	7.2	-8.2	26.9	17.5	-7.7	-14.3	-4.4	+42.8%
2016	-43.3	-0.4	23.4	4.2	-5.1	-16.0	19.7	-9.2	11.3	-16.9	14.5	20.9	−19.4%
2015	-11.8	-9.8	20.0	-31.0	2.5	30.9	-8.6	-26.0	38.8	-7.7	20.3	20.4	+11.0%
2014				24.6	-0.3	14.4	-20.3	1.7	-1.7	-41.4	-6.8	-3.6	−40.5%

INSD

Insider Activity · AKBA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

564.2K shares

Sells, 6 months

56K shares

Net shares

+508.2K

Net change in insider shares

+10.20%

Date	Insider	Transaction	Shares	Value
Aug 5, 2026	Butler John PChief Executive Officer	Conversion of Exercise of derivative security at price 0.63 per share.	350K	$220.50K
Jun 28, 2026	Ostrowski ErikChief Financial Officer	Sale at price 1.11 per share.	56K	$62.18K
Jun 16, 2026	Zumwalt Leanne MDirector	Stock Award(Grant) at price 0.00 per share.	35.7K	—
Jun 16, 2026	Smith CynthiaDirector	Stock Award(Grant) at price 0.00 per share.	35.7K	—
Jun 16, 2026	Rogers Michael WDirector	Stock Award(Grant) at price 0.00 per share.	35.7K	—
Jun 16, 2026	Adams AdrianDirector	Stock Award(Grant) at price 0.00 per share.	35.7K	—
Jun 16, 2026	Wolf MylesDirector	Stock Award(Grant) at price 0.00 per share.	35.7K	—
Jun 16, 2026	Frieson RonDirector	Stock Award(Grant) at price 0.00 per share.	35.7K	—
Mar 3, 2026	Butler John PChief Executive Officer	Purchase at price 1.25 per share.	69.3K	$86.59K
Feb 1, 2026	Butler John PChief Executive Officer	Stock Award(Grant) at price 1.41 per share.	175.3K	$247.10K
Feb 1, 2026	Burke Steven KeithOfficer	Sale at price 1.39 per share.	67.7K	$94.05K
Feb 1, 2026	Butler John PChief Executive Officer	Sale at price 1.39 per share.	341.3K	$474.41K
Feb 1, 2026	Grund NicholasOfficer	Sale at price 1.39 per share.	84.8K	$117.91K
Feb 1, 2026	Ostrowski ErikChairman of the Board	Sale at price 1.39 per share.	35K	$48.58K
Feb 1, 2026	Malabre Richard C.Officer	Sale at price 1.39 per share.	49.5K	$68.84K
Feb 1, 2026	Rucci Carolyn MOfficer	Sale at price 1.39 per share.	69.8K	$96.98K
Jan 29, 2026	Burke Steven KeithOfficer	Stock Award(Grant) at price 0.00 per share.	204K	—
Jan 29, 2026	Butler John PChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	743K	—
Jan 29, 2026	Grund NicholasOfficer	Stock Award(Grant) at price 0.00 per share.	204K	—
Jan 29, 2026	Ostrowski ErikChairman of the Board	Stock Award(Grant) at price 0.00 per share.	204K	—

13F

Investors Holding AKBA

latest 13F filings of 29 followed managers

Investors holding AKBA
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.4M	0.00%	1.22M	−33%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

AKBA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AKBA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Akebia Therapeutics, Inc.

Seasonality · AKBA

Insider Activity · AKBA

Congress Trades · AKBA

Investors Holding AKBA

Investors Holding AKBA

Congress Trades · AKBA

Insider Activity · AKBA

Seasonality · AKBA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Akebia Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News